Dublin, April 09, 2019 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
The regenerative medicine market is projected to reach USD 38.70 billion by 2024 from USD 13.31 billion in 2019, at a CAGR of 23.8%.
Regenerative medicines are developed using tissue engineering and molecular biology and are used for the treatment of different chronic disorders.Market growth is largely driven by the rising prevalence of chronic diseases and genetic disorders, growing government investments in regenerative medicine research, and the increasing number of regenerative medicine companies globally. The Cures Act, the growing demand for organ transplantation, and the emerging countries are expected to provide a wide range of growth opportunities for players in the market.
On the other hand, ethical concerns with the use of embryonic stem cells for R&D may limit market growth to a certain extent in the coming years.
In this report, the regenerative market is segmented into type, application, and region. The regenerative medicine market is a highly fragmented market and is dominated by various players offering regenerative medicine therapies and tissue-derived regenerative products.
The major players in this market are Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US).
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Regenerative Medicine: Market Overview
4.2 Regenerative Medicine Market, By Type & Application (2019)
4.3 Geographical Snapshot of the Regenerative Medicine Market
5 Market Overview
5.1 Introduction
5.2 Clinical Trials for Regenerative Medicine
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Prevalence of Chronic Diseases and Genetic Disorders
5.3.1.2 Rising Government Investments in Regenerative Medicine Research
5.3.1.3 Product Approvals and Growing Pipeline of Regenerative Medicine Products
5.3.2 Restraints
5.3.2.1 Ethical Concerns Related to the Use of Embryonic Stem Cells in Research & Development
5.3.3 Opportunities
5.3.3.1 Implementation of the 21st Century Cures Act
5.3.3.2 Rising Demand for Organ Transplantation
6 Regenerative Medicine Market, By Type
6.1 Introduction
6.2 Cell-Based Immunotherapy & Cell Therapy Products
6.2.1 Allogeneic Products
6.2.2 Autologous Products
6.3 Tissue-Engineered Products
6.4 Gene Therapy Products
7 Regenerative Medicine Market, By Application
7.1 Introduction
7.2 Musculoskeletal Disorders
7.2.1 Musculoskeletal Disorders Segment Will Continue to Dominate the Regenerative Medicine Market in 2024
7.3 Wound Care
7.3.1 Increasing Prevalence of Target Conditions to Drive the Growth of This Application Segment
7.4 Oncology
7.4.1 Increasing Prevalence of Cancer to Support Market Growth
7.5 Ocular Disorders
7.5.1 Growing Number of Product Approvals to Support Market Growth
7.6 Diabetes
7.6.1 Increasing Incidence of Diabetes and the Growing Focus of Companies on Developing Regenerative Medicine for the Treatment of Diabetes are the Key Factors Driving Market Growth
7.7 Other Applications
8 Regenerative Medicine Market, By Region
9 Competitive Landscape
9.1 Overview
9.2 Market Ranking Analysis, 2017
9.3 Key Strategies
9.4 Competitive Leadership Mapping (2018)
9.5 Competitive Leadership Mapping for Start-Ups (2018)
10 Company Profiles
- Integra Lifesciences
- Kite Pharma (Subsidiary of Gilead Sciences)
- Mimedx Group
- Novartis AG
- Organogenesis
- Osiris Therapeutics
- Spark Therapeutics
- Stryker
- Vericel
- Wright Medical
For more information about this report visit https://www.researchandmarkets.com/r/ftyanl
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.